Focal Reirradiation for Prostate Cancer: A New Approach After Surgery and Salvage Radiation Failure

What is it about?

This research discusses a study on focal reirradiation with brachytherapy for prostate cancer patients who have experienced a second local relapse after radical prostatectomy and salvage external beam radiation therapy. The study enrolled seven patients with isolated prostatic bed relapse, visible on imaging. The procedure involved TRUS-guided biopsy, MRI-TRUS fusion, and intra-operative MRI for verification and dosimetry. A dose of 27.0 Gy in two daily fractions was prescribed, with specific constraints for organs at risk. The study reports promising results, with a median biochemical relapse-free survival of 36 months and no grade ≥2 toxicities observed. The authors compare their findings to limited available literature, mainly based on stereotactic body radiation therapy, and suggest that focal reirradiation with brachytherapy may be a viable option for selected patients with isolated prostatic bed relapse.

Featured Image

Why is it important?

This research is significant because it explores a novel approach to treating isolated prostatic bed relapse (IPBR) in prostate cancer patients who have already undergone radical prostatectomy (RP) and salvage external beam radiation therapy (EBRT). The study investigates the use of focal high-dose-rate (HDR) brachytherapy as a second salvage treatment option, which could provide an alternative to androgen deprivation therapy (ADT) for patients with limited local treatment options. This approach has the potential to improve patient outcomes and quality of life by offering a localized treatment option for recurrent prostate cancer. Key Takeaways: 1. Novel Treatment Approach: The study presents focal HDR brachytherapy as a viable second salvage treatment for IPBR in prostate cancer patients, offering an alternative to systemic treatments like ADT. 2. Improved Imaging Techniques: The research highlights the importance of advanced imaging techniques such as 68 Ga PSMA-PET and multiparametric MRI in accurately detecting and targeting recurrent lesions, enabling more precise and effective treatment. 3. Promising Outcomes: Initial results from the study show encouraging biochemical control rates and low toxicity profiles, suggesting that focal HDR brachytherapy could be a safe and effective option for carefully selected patients with IPBR after RP and salvage EBRT.